MedTrace Logo

Intracoronary Human Wharton's Jelly- Derived Mesenchymal Stem Cells (WJ-MSCs) Transfer in Patients With Acute Myocardial Infarction (AMI)

NCT01291329 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 160

Last updated 2015-02-13

No results posted yet for this study

Summary

The purpose of this study is to investigate the safety and efficacy of intracoronary human umbilical Wharton's jelly-derived mesenchymal stem cell (WJ-MSC) transfer in patients with ST-segment elevation acute myocardial infarction.

Conditions

  • ST-Elevation Myocardial Infarction

Interventions

GENETIC

intracoronary human umbilical WJ-MSC transfer

intracoronary infusion of WJ-MSCs or placebo medium into the infarct artery 4-7 days after successful reperfusion therapy.

Sponsors & Collaborators

  • Chinese PLA General Hospital

    collaborator OTHER

  • General Hospital of Chinese Armed Police Forces

    collaborator OTHER

  • First People's Hospital of Foshan

    collaborator OTHER

  • Navy General Hospital, Beijing

    lead OTHER

Principal Investigators

  • Lian Ru Gao, MD · Cardiology Division of Navy General Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-02-28
Primary Completion
2012-02-29
Completion
2012-07-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01291329 on ClinicalTrials.gov